212 related articles for article (PubMed ID: 26303714)
1. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
Bodei L; Kidd M; Prasad V; Modlin IM
Front Horm Res; 2015; 44():198-215. PubMed ID: 26303714
[TBL] [Abstract][Full Text] [Related]
2. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.
Bodei L; Kwekkeboom DJ; Kidd M; Modlin IM; Krenning EP
Semin Nucl Med; 2016 May; 46(3):225-38. PubMed ID: 27067503
[TBL] [Abstract][Full Text] [Related]
3. Peptide-receptor radionuclide therapy for endocrine tumors.
van Essen M; Krenning EP; Kam BL; de Jong M; Valkema R; Kwekkeboom DJ
Nat Rev Endocrinol; 2009 Jul; 5(7):382-93. PubMed ID: 19488074
[TBL] [Abstract][Full Text] [Related]
4. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
Bodei L; Cremonesi M; Kidd M; Grana CM; Severi S; Modlin IM; Paganelli G
Thorac Surg Clin; 2014 Aug; 24(3):333-49. PubMed ID: 25065935
[TBL] [Abstract][Full Text] [Related]
5. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
Kwekkeboom DJ; Krenning EP
Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
[TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
7. Myeloid neoplasms after chemotherapy and PRRT: myth and reality.
Bodei L; Modlin IM; Luster M; Forrer F; Cremonesi M; Hicks RJ; Ezziddin S; Kidd M; Chiti A
Endocr Relat Cancer; 2016 Aug; 23(8):C1-7. PubMed ID: 27353035
[TBL] [Abstract][Full Text] [Related]
8. Peptide receptor radionuclide therapy of neuroendocrine tumours.
Brabander T; Teunissen JJ; Van Eijck CH; Franssen GJ; Feelders RA; de Herder WW; Kwekkeboom DJ
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):103-14. PubMed ID: 26971847
[TBL] [Abstract][Full Text] [Related]
9. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
10. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.
Sabet A; Khalaf F; Yong-Hing CJ; Sabet A; Haslerud T; Ahmadzadehfar H; Guhlke S; Grünwald F; Biersack HJ; Ezziddin S
Nuklearmedizin; 2014; 53(2):54-9. PubMed ID: 24777355
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
[TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.
Alsadik S; Yusuf S; Al-Nahhas A
Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538
[TBL] [Abstract][Full Text] [Related]
13. Radionuclide Therapy for Neuroendocrine Tumors.
Cives M; Strosberg J
Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
[TBL] [Abstract][Full Text] [Related]
14. Yttrium-based therapy for neuroendocrine tumors.
Bodei L; Cremonesi M; Paganelli G
PET Clin; 2014 Jan; 9(1):71-82. PubMed ID: 25029936
[TBL] [Abstract][Full Text] [Related]
15. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.
Halperin DM; Dasari A; Yao JC
Future Oncol; 2016 Feb; 12(3):313-21. PubMed ID: 26759064
[TBL] [Abstract][Full Text] [Related]
16. Personalized
Del Prete M; Buteau FA; Beauregard JM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
[TBL] [Abstract][Full Text] [Related]
17. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
18. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
[TBL] [Abstract][Full Text] [Related]
19. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
[TBL] [Abstract][Full Text] [Related]
20. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]